SHIONOGI INC.

CEFIDEROCOL REQUEST FOR EMERGENCY USE

Thank you for contacting Shionogi Inc. regarding accessing cefiderocol for your patient. Shionogi Inc. offers an Early Access Program for cefiderocol (special access for Canada) for patients with limited or no other appropriate therapeutic options. This program is operated by Shionogi Inc.'s partner, Inceptua Group (Inceptua).

Please be aware that cefiderocol is not currently approved for use in Canada and all such requests for cefiderocol access require approval from Health Canada.

Fetroja® (cefiderocol) is approved in the United States (US) for use in patients 18 years of age or older for the treatment of:[1]

- complicated urinary tract infections (cUTIs), including pyelonephritis caused by the following susceptible Gram-negative microorganisms: *Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa,* and *Enterobacter cloacae* complex
- hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by the following susceptible Gram-negative microorganisms: *Acinetobacter baumannii* complex, *Escherichia coli, Enterobacter cloacae* complex, *Klebsiella pneumoniae, Pseudomonas aeruginosa,* and *Serratia marcescens*

A copy of the approved United States Prescribing Information (USPI) is attached.

All requests for the Early Access Program to cefiderocol must be made by the treating physician or pharmacist, through Inceptua's request portal, called Imap. The link to Imap is provided below:

https://portal.inceptua.com/

Please register on the Imap portal and follow the instructions to be guided through the registration and request process. ***To assist you with this process, we have included the following documents: HCP Guide to Imap Portal and Cefiderocol Early Access Program – Frequently Asked Questions.*** If you have any questions about registration, the request process, import, or regulatory approvals please contact the Inceptua Medicines Access Advisor team at:

access@inceptua.com
1.646.307.9760

If you have any medical questions regarding cefiderocol, please contact Shionogi Medical Information at:

medinfo@shionogi.com
1.800.849.9707

400 Campus Drive, 4th Floor
Florham Park, NJ 07932

SHIONOGI INC.

REFERENCE

1. Fetroja® (cefiderocol) for injection, for intravenous use [Prescribing Information]. Shionogi Inc.

ENCLOSURE

Fetroja® (cefiderocol) for injection, for intravenous use [Prescribing Information]. Shionogi Inc.

HCP Guide to Imap Portal

Cefiderocol Early Access Program – Frequently Asked Questions

400 Campus Drive, 4th Floor
Florham Park, NJ 07932